Interní Med. 2016; 18(4): 198-202 | DOI: 10.36290/int.2016.045

Chronic obstructive pulmonary disease - benefit of dual bronchodilator therapy

MUDr.Václava Bártů, Ph.D.

Plicní oddělení, Medicon a. s.

Obstructive ventilatory defect that is not fully reversible following the administration of a rapid-acting bronchodilator is a significant

feature of chronic obstructive pulmonary disease (COPD). Inhaled long-acting and ultralong-acting ß2 agonists (LABAs, U-LABAs)

as well as inhaled long-acting and ultralong-acting muscarinic receptor antagonists (LAMAs, U-LAMAs) are the mainstay medications

in treating COPD based on the disease stage and patient’s symptoms (1). This is blanket therapy. However, in the situation

when disease symptoms and their frequency fail to be reduced with a monocomponent drug, dual combination is indicated that

is of more benefit than merely increasing the dose of one agent (2, 3). The combination of aclidinium bromide and formoterol

fumarate is administered by means of the Genuair inhaler system. The agent referred to as Brimica or Duaklir represents the dual

bronchodilator therapeutic approach in treating COPD (4, 5).

The present case report deals with evaluation of anamnestic data, objective findings, and pulmonary function test results in a former

smoker patient in the course of COPD. The patient mainly suffered from typical complaints, particularly exertional dyspnoea and

cough that were not easily manageable. Over the years, the treatment was modified and adjusted. The aim was, in particular, to

improve the quality of life and reduce the patient’s chronic complaints. It was the inhaled administration of dual bronchodilator

therapy that made it possible to achieve this status

Keywords: chronic obstructive pulmonary disease, dual bronchodilator therapy, aclidinium bromide, formoterol fumarate, Genuair

Published: September 1, 2016  Show citation